

LETTER TO THE EDITORS

ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient

doi:10.1111/tri.12427

Dear Sirs,

At the time of severe shortage of deceased donors, continuous efforts are needed to avoid discarding potential living donors. Anti-hepatitis C virus (HCV)-positive donors are not considered suitable candidates for living kidney donation [1]. However, little is known regarding outcomes of such a procedure. Watanabe *et al.* [2] reported successful living kidney transplantation from an anti-HCV antibody-positive-HCV RNA-negative donor into an anti-HCV antibody-negative recipient. Donor and recipient were one HLA identical haplotype, ABO identical and immunosuppression was low. At 24 months post-transplant, the recipient was free of liver disease with negative HCV RNA. Increased mortality risk has only been studied among recipients of anti-HCV antibody-positive kidneys retrieved from deceased donors [3].

A 66-year-old male, blood type O, had been on dialysis since 2007 for cholesterol emboli nephropathy. Evaluation of his 62-year-old wife, blood type A, showed positive anti-HCV antibodies in serum (cutoff index $4.7 > 1.0$; enzyme immunoassay), HCV RNA detection by RT-PCR inferior to 15 UI/ml (undetectable defined as < 15 UI/ml), normal serum liver enzymes, and Fibroscan. A multidisciplinary round was agreed on the transplantation, and informed consent was obtained from both the donor and the recipient.

Immunosuppression consisted of 375 mg/m² rituximab 4 weeks before the transplantation, tacrolimus, mycophenolate mofetil and prednisolone starting 1 week preoperatively, and basiliximab induction. As anti-A antibodies were below 1:8, specific immunoadsorption was not required. The transplantation was successful with a serum creatinine level of 86 μ mol/L at discharge.

At follow-up, *Norovirus* enteritis was diagnosed at day 21 and asymptomatic cytomegalovirus reactivation at day 30. One year post-transplant, the recipient's liver function tests remained normal, anti-HCV antibodies were negative, and HCV RNA was undetectable. A liver biopsy was not

deemed indicated. Protocol kidney biopsies performed at 3 and 12 months showed no rejection.

To our knowledge, we report the first ABO incompatible kidney transplantation from an anti-HCV antibody-positive-HCV RNA-negative donor into an anti-HCV antibody-negative recipient. Even with high immunosuppression level, our recipient was free of liver disease and HCV acute infection at one year follow-up.

Presence of serum HCV RNA seems to better predict the risk of HCV transmission by kidney transplantation [4]. It was however not used in initial studies evaluating the risk associated with using HCV-positive kidneys in organ transplantation [3]. Potential donors who had HCV exposure without HCV infection might not transmit the virus.

We advocate the fact that anti-HCV antibody-positive-RNA-negative people, whether spontaneously or after antiviral therapy, deserve consideration for living kidney donation. Outcomes of patients receiving HCV-positive kidneys versus patients remaining on the transplant waiting list should be studied, with comprehensive analyses of competing risks [1].

Yassine Bouatou¹, Francesco Negro² and Karine Hadaya^{1,3}

1 Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland

2 Divisions of Gastroenterology and Hepatology and of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland

3 Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland

e-mail: Karine.Hadaya@hcuge.ch

Conflicts of interest

The authors of this manuscript have no conflicts of interest to disclose as described by the *Transplant International* journal.

References

1. Seem DL, Lee I, Umscheid CA, Kuehnert MJ. Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation. *Am J Transplant* 2013; **13**: 1953 Epub 2013/07/31.
2. Watanabe T, Koyama I, Shinozuka N, *et al.* A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. *Transpl Proc* 2000; **32**: 1593 Epub 2000/12/20.
3. 1Bucci JR, Matsumoto CS, Swanson SJ, *et al.* Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. *J Am Soc Nephrol* 2002; **13**: 2974 Epub 2002/11/22.
4. Pereira BJ, Wright TL, Schmid CH, *et al.* Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. *Kidney Int* 1994; **46**: 886 Epub 1994/09/01.